They all had severe disease and a high treatment burden with an average of 10 injections with Eylea (aflibercept), a widely-used VEGF inhibitor sold by Bayer and Regeneron, in the last 12 months.

Approval for Eylea for diabetic retinopathy was based on six-month and one-year trial results from PANORAMA, a phase 3 trial that enrolled 402 patients comparing the drug with placebo.

Flattening sales in the Eylea ophthalmology franchise were more than offset by strong sales from immunology drug Dupixent and oncology drug Libtayo. Despite strong competitive pressures facing the ...